Synthesis and In Vitro (Anticancer) Evaluation of eta(6)-Arene Ruthenium Complexes Bearing Stannyl Ligands
Graph Chatbot
Chat with Graph Search
Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
The long-term risk of malignancy associated with stem cell therapies is a significant concern in the clinical application of this exciting technology. We report a cancer-selective strategy to enhance the safety of stem cell therapies. Briefly, using a cell ...
The developmental potential of human pluripotent stem cells suggests that they can produce disease-relevant cell types for biomedical research. However, substantial variation has been reported among pluripotent cell lines, which could affect their utility ...
Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established anticancer compounds. Transferring this concept to ruthenium complexes led to the synthesis of dinuclear Ru(II)-arene compounds containing a bis(pyridinone ...
Investigations of ruthenium halfsandwich complexes have mostly focused on Cp and Cp* based derivatives due to the availability of easily accessible starting materials. However, it is interesting to have complexes with substituted cyclopentadienyl ligands i ...
Current research in the biotechnological field is hampered by the lack of available technologies dedicated to cell monitoring. While on the one hand physicochemical parameters, such as pH, temperature, cell density and adhesion, can be monitored quite easi ...
New cationic diruthenium complexes of the type [(arene)2Ru2(SPh)3]+, arene being C6H6, p-iPrC6H4Me, C6Me6, C6H5R, where R = (CH2)nOC(O)C6H4-p-O(CH2)6CH3 or (CH2)nOC(O)CH:CHC6H4-p-OCH3 and n = 2 or 4, are obtained from the reaction of the corresponding prec ...
In recent years, ruthenium-based antitumour drugs have emerged as an attractive alternative to cisplatin, exhibiting both excellent activity in tumours where cisplatin is of limited use and low general toxicity, leading to reduced side effects. Two rutheni ...
A series of cationic dinuclear p-cymene ruthenium trithiophenolato complexes of the type (eta(6)-p-MeC6H4Pr (i) )(2)Ru-2(SC6H4-p-X)(3) (1 X is H, 2 X is Me, 3 X is Ph, 4 X is Br, 5 X is OH, 6 X is NO2, 7 X is OMe, 8 X is CF3, 9 X is F, 10 X is Pr (i) ...
